The Ohio Valley Node (OVN) joined NIDA's Clinical Trials Network (CTN) four years ago, as one of the CTN's second wave of grantees. From the very beginning, the OVN has been a highly effective, enthusiastic, and energetic node that has excelled in providing scientific and administrative leadership, in collaborating with other nodes and with NIDA staff, and in disseminating information about evidence-based practice and the results of CTN studies. Moreover, the OVN has developed a model bi-directional relationship between its University of Cincinnati-affiliated Regional Research and Training Center (RRTC) and its six original (""""""""core"""""""") community treatment programs (CTPs), which are located in Ohio, Indiana, Kentucky, and West Virginia. In this continuation application, the OVN proposes to enhance the geographical and cultural diversity of the CTN by expanding the OVN's Midwestern and Appalachian presence in the network and adding a Mississippi Delta component, via nine additional """"""""protocol-specific"""""""" CTPs in five additional states. The fifteen OVN CTPs, which together treat more than 52,000 patients a year, will contribute significantly to the number and variety of potential participants for CTN studies. Each of the core OVN CTPs has participated in at least one CTN clinical trial and two survey studies and all six will continue to share in the administration of the node and in its development of research concepts and protocols. Although the new protocol-specific CTPs will play a more limited role, they are looking forward with enthusiasm to participating in appropriate clinical trials, providing an expanded and enriched patient population to the CTN. During the OVN's first four years in the CTN, we have immersed ourselves fully in all of its activities. We have submitted nine protocol concepts, of which five were chosen for further development;two have been converted into full protocols, including one which is currently enrolling participants. We have been active in the national committees of the CTN, providing five committee chairs and authoring or contributing to many SOPs and """"""""guidance"""""""" documents. Unique contributions by the OVN include a system used CTN-wide for monitoring and reporting on staff training requirements and accomplishments, a system for tracking the progress of CTN clinical trials, and a template used to standardize the organization of CTN node budgets. The sense of satisfaction we feel in these and other accomplishments, together with the urgency we feel to continue working on the important search for effective treatments for substance abuse, make us eager to continue the work we have begun.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZDA1-MXG-S (02))
Program Officer
Dobbins, Ronald
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Cincinnati
Schools of Medicine
United States
Zip Code
Garrett, Sharon B; Doyle, Suzanne R; Peavy, K Michelle et al. (2018) Age differences in outcomes among patients in the ""Stimulant Abuser Groups to Engage in 12-Step"" (STAGE-12) intervention. J Subst Abuse Treat 84:21-29
Levran, Orna; Correa da Rosa, Joel; Randesi, Matthew et al. (2018) A non-coding CRHR2 SNP rs255105, a cis-eQTL for a downstream lincRNA AC005154.6, is associated with heroin addiction. PLoS One 13:e0199951
Winhusen, Theresa; Feaster, Daniel J; Duan, Rui et al. (2018) Baseline Cigarette Smoking Status as a Predictor of Virologic Suppression and CD4 Cell Count During One-Year Follow-Up in Substance Users with Uncontrolled HIV Infection. AIDS Behav 22:2026-2032
Trivedi, Madhukar H; Greer, Tracy L; Rethorst, Chad D et al. (2017) Randomized Controlled Trial Comparing Exercise to Health Education for Stimulant Use Disorder: Results From the CTN-0037 STimulant Reduction Intervention Using Dosed Exercise (STRIDE) Study. J Clin Psychiatry 78:1075-1082
Lévesque, Annie; Campbell, Aimee N C; Pavlicova, Martina et al. (2017) Coping strategies as a mediator of internet-delivered psychosocial treatment: Secondary analysis from a NIDA CTN multisite effectiveness trial. Addict Behav 65:74-80
Korthuis, Philip T; Lum, Paula J; Vergara-Rodriguez, Pamela et al. (2017) Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial. Addiction 112:1036-1044
Pan, Yue; Liu, Hongmei; Metsch, Lisa R et al. (2017) Factors Associated with HIV Testing Among Participants from Substance Use Disorder Treatment Programs in the US: A Machine Learning Approach. AIDS Behav 21:534-546
Osterman, Robin; Lewis, Daniel; Winhusen, Theresa (2017) Efficacy of motivational enhancement therapy to decrease alcohol and illicit-drug use in pregnant substance users reporting baseline alcohol use. J Subst Abuse Treat 77:150-155
Blanco, Carlos; Campbell, Aimee N; Wall, Melanie M et al. (2017) Toward National Estimates of Effectiveness of Treatment for Substance Use. J Clin Psychiatry 78:e64-e70
Worley, Matthew J; Heinzerling, Keith G; Shoptaw, Steven et al. (2017) Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction. Addiction 112:1202-1209

Showing the most recent 10 out of 133 publications